Nipocalimab for children with generalized myasthenia gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial studies nipocalimab, an immune-focused medicine, to see if it can improve generalized myasthenia gravis (gMG) in children ages 2 to under 18. It may help reduce weakness caused by this autoimmune muscle disease, but you must meet specific antibody and health requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 2 and under 18 years old (and for US sites, 8 to under 18).
- Your child has generalized myasthenia gravis (gMG) with muscle weakness that fits the trial’s classification.
- Blood tests show either anti–AChR or anti–MuSK antibodies are positive.
- Your child can have IV infusions and blood draws (enough vein access).
- Your child’s weight is typically between the 5th and 95th percentile for age/sex, or a doctor clears outside this range.
- If your child could get pregnant, pregnancy tests must be negative before starting study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests nipocalimab, a medication given by infusion (and in some groups by injections under the skin), to improve symptoms in adults with generalized myasthenia gravis (MG). It may help reduce weakness in daily activities, especially if you meet specific symptom and safety criteria.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.